Get notified of page updates

Enroll in Research > Research Search & Enroll Tool > Nivolumab, Nivolumab Plus Ipilimumab, or Chemotherapy for Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (CheckMate 8HW)

Glossary on

off

Printer Friendly Page

Nivolumab, Nivolumab Plus Ipilimumab, or Chemotherapy for Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (CheckMate 8HW)

Clinicaltrials.gov identifier:
NCT04008030

People with metastatic colorectal cancer that is MSI-High

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW)

About the Study

NOTE: This study is no longer recruiting patients.

The purpose of this study is to compare the benefit of the combination of agents nivolumab (Opdivo) plus ipilimumab (Yervoy) in patients who have High (MSI-H) or Mismatch Repair Deficient () colorectal cancer versus using nivolumab as a single therapy or chemotherapy.

This Study is Open To:

NOTE: This study is no longer recruiting patients.

This Study is Not Open To:

NOTE: This study is no longer recruiting patients.